Expense

FHLB Des Moines Announces Capital Stock Requirement Changes and Third Quarter 2023 Dividend and Financial Results

Retrieved on: 
Thursday, October 26, 2023
Asset, Insurance, Bank, Housing, Organization, Investment, Growth, Expense, National Capital Planning Commission, AHP, Partnership, Government, Capital, Cryptocurrency

On October 26, 2023, the Bank announced changes to its requirements for membership stock and activity stock on outstanding advances pursuant to its Capital Plan.

Key Points: 
  • On October 26, 2023, the Bank announced changes to its requirements for membership stock and activity stock on outstanding advances pursuant to its Capital Plan.
  • In addition, the Bank will be increasing its activity stock requirement on advances only from 4.00 percent to 4.50 percent.
  • The Board of Directors approved a third quarter 2023 dividend at an annualized rate of 8.50 percent on activity-based stock, an increase of 0.55 percent from the prior quarter, and 3.00 percent on membership stock, unchanged from the prior quarter.
  • Dividend payments totaling $123 million, based on average stock outstanding during the third quarter of 2023, are expected to be paid on November 13, 2023.

Sterling Bancorp Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, October 25, 2023
Banking, Professional Services, Finance, Insurance, Instability, Sale, SBT, Bank, History of the Federal Reserve System, Federal Reserve Bank of Chicago, Government, Pressure, United States Department of Justice, Fraud, Sterling Bank, Federal Reserve Bank, Environment, Sterling Bancorp, Trust, NOW, Expense, Risk, Webcast, District court, Federal Reserve, Recovery, F.S.B, Current Expected Credit Losses, Total, Plea, Sterling, Cryptocurrency

Sterling Bancorp, Inc. (NASDAQ: SBT) (“Sterling” or the “Company”), the holding company of Sterling Bank and Trust, F.S.B.

Key Points: 
  • Sterling Bancorp, Inc. (NASDAQ: SBT) (“Sterling” or the “Company”), the holding company of Sterling Bank and Trust, F.S.B.
  • (the “Bank”), today reported its unaudited financial results for the third quarter ended September 30, 2023.
  • The net interest margin of 2.62% for the third quarter of 2023 decreased slightly from the net interest margin of 2.64% for the second quarter of 2023.
  • Non-Interest Expense – Non-interest expense of $17.7 million for the third quarter of 2023 reflected an increase of $0.4 million, or 2%, compared to the second quarter of 2023.

The North West Company Inc. Announces Second Quarter Earnings and an Increase in the Quarterly Dividend

Retrieved on: 
Tuesday, September 12, 2023
Food, Tesco international operations, Interest, Mercantile Stores Company, Inc., GAAP, EBIT, Expense, EBITDA, Depreciation, TSX, Growth, The Company, NWC, Bank, Bookkeeping

WINNIPEG, Manitoba, Sept. 12, 2023 (GLOBE NEWSWIRE) -- (TSX: NWC): The North West Company Inc. (the "Company" or "North West") today reported its unaudited financial results for the second quarter ended July 31, 2023.

Key Points: 
  • WINNIPEG, Manitoba, Sept. 12, 2023 (GLOBE NEWSWIRE) -- (TSX: NWC): The North West Company Inc. (the "Company" or "North West") today reported its unaudited financial results for the second quarter ended July 31, 2023.
  • “I am optimistic about the progress we are making on our operational excellence priorities and the growth potential of our business.
  • Gross Profit Gross profit increased 11.1% driven by sales gains and a 128 basis point increase in gross profit rate compared to last year.
  • The Company uses the following non-GAAP financial measures: earnings before interest, income taxes, depreciation and amortization ("EBITDA"), adjusted EBITDA and adjusted net earnings.

LICT Corporation Reports Second Quarter 2023 Results and August 31 Spin-off of Michigan Property – 150 Shares of MachTen Per One Share of LICT Corporation

Retrieved on: 
Friday, September 1, 2023
Technology, Mobile, Wireless, Telecommunications, VoIP, CONNECT, Digital divide, OTC Markets Group, Enhanced, Federal Communications Commission, ILEC, FCC, United States Department of Agriculture, Incumbent local exchange carrier, Internet, AMERICA, Federal, MACT, LICT, Public expenditure, Expense, EBITDA, SHARE, Data-rate units, USDA, MachTen, OTC, Growth, Corporate spin-off, ACP, Video game, Internet service provider

LICT Corporation (“LICT” or the “Company”; OTC Pink®: LICT) reports unaudited, financial results for the quarter ended June 30, 2023.

Key Points: 
  • LICT Corporation (“LICT” or the “Company”; OTC Pink®: LICT) reports unaudited, financial results for the quarter ended June 30, 2023.
  • Regulated revenues were $14.7 million in the second quarter of 2023 versus the prior year’s second quarter of $15.0 million.
  • Other Income (Expense) – Other income/expenses were $500,000 in the second quarter of 2023, versus $400,000 in the prior year’s second quarter.
  • At the time of the spin-off each shareholder of LICT received 150 shares of MachTen per one share of LICT.

Altus Power, Inc. Announces Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Alternative Energy, Energy, Utilities, ASC, Partnership, Bank statement, Altus, NMCA, GAAP, Interest expense, Accounting, REC, Entity, Alignment, Mergers and acquisitions, Monte Carlo, Expense, EBITDA, PAR, Retirement, Accretion expense, Depreciation, Annual report, Professional, Earnout, Growth, Community solar, PPA, NYSE, Acquisition, Renewable energy, Insurance, Bookkeeping, Security (finance), Power

Altus Power, Inc. (NYSE: AMPS) (“Altus Power,” “we,” “us,” “our,” or the “Company”), the leading commercial-scale provider of clean electric power, today announced its financial results for the second quarter of 2023.

Key Points: 
  • Altus Power, Inc. (NYSE: AMPS) (“Altus Power,” “we,” “us,” “our,” or the “Company”), the leading commercial-scale provider of clean electric power, today announced its financial results for the second quarter of 2023.
  • Second quarter 2023 GAAP net income totaled $3.4 million, compared to $21.6 million for the same period last year.
  • Adjusted EBITDA* during the second quarter of 2023 was $30.6 million, compared to $13.9 million for the second quarter of 2022, a 120% increase.
  • Altus Power reaffirmed 2023 adjusted EBITDA* in the range of $97-103 million, representing 70% growth over 2022 at the midpoint.

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Friday, August 11, 2023
Insulin, RAGE, Research and development, VTV, G&A, Expense, Administration, R, FDA, General Administration of Sport of China, Therapy, Breakthrough, Pharmaceutical industry

HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
  • Cash Position: The Company’s cash position as of June 30, 2023, was $12.6 million compared to $12.1 million as of December 31, 2022.
  • Net Loss: Net loss attributable to vTv shareholders for the three months ended June 30, 2023, was $5.6 million or $0.07 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $3.2 million or $0.04 per basic share.

Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Friday, August 11, 2023
National Center for Health Research, MIND, Partnership, Shareholder, State Administrative Expenses, Marketing, Bank statement, Eastern Time Zone, Biotechnology, Survival, Clinical trial, Research, Hypoplastic left heart syndrome, Biomarker, Inflammation, Șaeș, Shimaa Hashad, CLEAR, Development, Conference call, MRI, Expense, Magnetic resonance imaging, Patient, Investment, Cost, Mortality, AD, Geriatrics, Conference, Safety, Pharmaceutical industry, Rare-earth element, Nursing, Tutoring, Birth control, Cryptocurrency, HLHS

MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • Company to Hold Conference Call and Webcast Today, August 11, 2023 at 8am Eastern Time
    MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended June 30, 2023 and provided a corporate update.
  • In November 2022, Longeveron announced it had completed enrollment in its Phase 2a trial of Lomecel-B™ for the treatment of Alzheimer’s disease (AD).
  • The Company expects to share top line results from CLEAR MIND by October 2023.
  • ET to discuss the Company’s second quarter 2023 financial results and provide a business update.

Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Oncology, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, ARVO, ELISPOT, Partnership, Probability, University, AMD, Expense, Roche, Clinical trial, Geographic atrophy, Cancer Research UK, G&A, University of California, San Diego Performance-Based Skills Assessment, Research, GA, Genentech, Lung cancer, Interest, Patient, AbbVie, TASE, CIRM, Annual general meeting, NYSE American, VAC2, Webcast, Lineage Cell Therapeutics, Transplant, FDA, Therapy, IND, Disease, D, Pharmaceutical industry, Medical imaging, Ophthalmology

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter ended June 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter ended June 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.
  • “The Lineage team continued to execute across multiple fronts during the second quarter, advancing our clinical and preclinical cell transplant programs and supporting our valuable alliances,” stated Brian M. Culley, Lineage CEO.
  • We also reported positive clinical results from a Phase 1 study of VAC2 in non-small cell lung cancer alongside our partner, Cancer Research UK.
  • Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.

LiqTech International Announces Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Swimming, Partnership, DPF, ERP, Convertible, Silicon, Silicon carbide, Expense, Investment, Water, MEG, Memorandum of understanding, Growth, Transport, Hand, Geographic Locator Codes, Cryptocurrency, Video game, Fine chemical

BALLERUP, Denmark, Aug. 10, 2023 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the second quarter of 2023 for the period ended June 30, 2023.

Key Points: 
  • BALLERUP, Denmark, Aug. 10, 2023 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the second quarter of 2023 for the period ended June 30, 2023.
  • Revenue for quarter ended June 30, 2023, was $5.0 million, comparable to the $5.0 million reported in second quarter of 2022.
  • Total operating expenses for the quarter ended June 30, 2023 were $2.8 million compared to $4.7 million in the second quarter of 2022.
  • Other Income (Expense) for the quarter ended June 30, 2023 was $0.0 million compared to $(1.9) million in second quarter of 2022, with the change reflecting a gain on currency transactions and the early repayment of the Convertible Note in the second quarter of 2022.

Surrozen Provides Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Partnership, Therapy, Retina, Boehringer Ingelheim, Development, Regeneration, Expense, Administration, SAN, Research, Pharmaceutical industry, Cryptocurrency, WNT

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided second quarter 2023 financial results and corporate and pipeline updates.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided second quarter 2023 financial results and corporate and pipeline updates.
  • “During the second quarter of 2023, we made important progress in the Phase 1a clinical trials for our lead candidates, SZN-043 and SZN-1326,” said Craig Parker, President and Chief Executive Officer of Surrozen.
  • Financial Results for the Second Quarter Ended June 30, 2023
    Cash Position: Cash, cash equivalents and marketable securities for the second quarter ended June 30, 2023 were $53.4 million, compared to $61.7 million as of March 31, 2023.
  • Net Loss: Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period in 2022.